Grant: Doctoral: Vanier Canada Graduate Scholarships
University of Toronto
$150,000.00
Cardioprotective benefits of combination treatment with a sodium-glucose co-transporter-2 inhibitor and a glucagon-like peptide-1 receptor agonist.
EF 2018-19
Résumé
Heart disease remains a leading cause of death and disability, and heart attack due to blockages in the heart's major arteries remains the dominant mechanism. Optimal treatment requires rapid relief from such blockages, and thus restoring blood flow to minimize heart tissue damage. However, substantial tissue damage also occurs after restoration of blood flow, known as ischemia-reperfusion injury. As such, pharmacological or technical approaches that limit these complications are of interest. Indeed, ischemia-reperfusion injury accounts for ~50% of the final scar size following a heart attack, which is the strongest contributor to the patient's risk of subsequently developing heart failure. This research project seeks to address the unanswered questions and unmet needs for a condition for which there remains no clinically approved therapy, namely ischemia-reperfusion injury and the heart failure that follows such injury. We will be testing the beneficial actions of two distinct drug classes recently shown to reduce risk of major cardiac events in patients with type-2 diabetes, namely (i) the SGLT2i dapagliflozin and (ii) the GLP-1RA exenatide, a.k.a. exendin-4, in a pre-clinical mouse model of ischemia-reperfusion injury and heart failure. These studies will help us better understand and tailor drug therapy to a large patient population (with and without diabetes) at high risk of cardiac events, namely the clinical conditions of heart attack, ischemia-reperfusion and subsequent heart failure.
Programme
Doctoral: Vanier Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
396625
Name
Zarrin Khat Dorrin
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Cardioprotective benefits of combination treatment with a sodium-glucose co-transporter-2 inhibitor and a glucagon-like peptide-1 receptor agonist.
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Cardiology; Cellular Metabolism; Diabetes; Drug Therapy; Glucagon-Like Peptide-1 Receptor Agonist; Ischemia-Reperfusion Injury; Myocardial Infarction; Oxidative Stress; Sodium-Glucose Co-Transporter-2 Inhibitor; Tissue Remodelling
Abstract
Heart disease remains a leading cause of death and disability, and heart attack due to blockages in the heart's major arteries remains the dominant mechanism. Optimal treatment requires rapid relief from such blockages, and thus restoring blood flow to minimize heart tissue damage. However, substantial tissue damage also occurs after restoration of blood flow, known as ischemia-reperfusion injury. As such, pharmacological or technical approaches that limit these complications are of interest. Indeed, ischemia-reperfusion injury accounts for ~50% of the final scar size following a heart attack, which is the strongest contributor to the patient's risk of subsequently developing heart failure. This research project seeks to address the unanswered questions and unmet needs for a condition for which there remains no clinically approved therapy, namely ischemia-reperfusion injury and the heart failure that follows such injury. We will be testing the beneficial actions of two distinct drug classes recently shown to reduce risk of major cardiac events in patients with type-2 diabetes, namely (i) the SGLT2i dapagliflozin and (ii) the GLP-1RA exenatide, a.k.a. exendin-4, in a pre-clinical mouse model of ischemia-reperfusion injury and heart failure. These studies will help us better understand and tailor drug therapy to a large patient population (with and without diabetes) at high risk of cardiac events, namely the clinical conditions of heart attack, ischemia-reperfusion and subsequent heart failure.
Competitiondate
201810
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Zarrin Khat, Dorrin
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~